Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Chiome Bioscience's FCF Margin % or its related term are showing as below:
TSE:4583'
s FCF Margin % Range Over the Past 10 Years
Min: -793.38 Med: -235.83 Max: -128.16
Current: -201.78
During the past 13 years, the highest FCF Margin % of Chiome Bioscience was -128.16%. The lowest was -793.38%. And the median was -235.83%.
TSE:4583's FCF Margin % is ranked worse than 60.74% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs TSE:4583: -201.78
Chiome Bioscience FCF Margin % Related Terms
Chiome Bioscience FCF Margin % Historical Data
* Premium members only.
The historical data trend for Chiome Bioscience's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4583 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Chiome Bioscience's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiome Bioscience FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chiome Bioscience's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Chiome Bioscience's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chiome Bioscience (TSE:4583) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Chiome Bioscience and its competitors. According to the industry distribution chart, Chiome Bioscience ranks #577 out of 950 companies in the Biotechnology industry, placing it in the top 60.7%.
Is Chiome Bioscience's FCF Margin % too high?
Chiome Bioscience's current FCF Margin % is 0.00%. Based on the distribution chart, Chiome Bioscience ranks #577 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chiome Bioscience has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chiome Bioscience ranks #577 out of 950 companies for FCF Margin %. This places Chiome Bioscience in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Chiome Bioscience and its competitors. Chiome Bioscience's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Possible Value Trap. The stock's GF Value™ is 円106.02, compared to a current price of 円69.00 — trading 34.9% below its estimated fair value. The current FCF Margin % is 0.00%. Chiome Bioscience's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chiome Bioscience (TSE:4583) Overvalued in 2026?
Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued.
The current stock price of 円69.00 is trading 34.9% below its estimated GF Value™ of 円106.02.
GuruFocus considers Chiome Bioscience to be Possible Value Trap.
Key valuation signals for TSE:4583:
FCF Margin %: 0.00%
GF Value™: 円106.02 vs. price of 円69.00 (34.9% below fair value)
No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
38GF Score
Get the complete analysis for TSE:4583
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4583 has been successfully added to your 
